


FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY DOCKET NO.
TSRI 419.0 Con 1SERIAL NO.
09/081,522INFORMATION DISCLOSURE
STATEMENT BY APPLICANTAPPLICANT
Brooks, et al.FILING DATE
May 19, 1998GROUP
1644

U.S. PATENT DOCUMENTS

EXAM. INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
PC	5,575,815	11/19/96	Slepian, et al.			OCT 15 2001
	5,849,692	12/15/98	Jonczyk, et al.			
	5,968,902	10/19/99	Scarborough, et al.			
	5,981,478	11/9/99	Ruoslahti, et al.			
	5,866,540	2/2/99	Jonczyk, et al.			
	5,135,919	8/4/92	Folkman, et al.			

FOREIGN PATENT DOCUMENTS

EXAM. INITIALS	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
	95/28426	10/26/95	PCT			
	97/14716	4/24/97	PCT			
	0 770 622 A	5/2/97	EPO			
	89/06536	7/27/89	PCT			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

	1	Matsuno, et al., Inhibition of integrin function by a cyclic RGD-containing peptide prevents neointima formation, 1994, <i>Circulation</i> , 90(5):2203-2205.
	2	Timar, et al., The antimetabolite tiazofurin (TR) inhibits glycoconjugate biosynthesis and invasiveness of tumour cells, 1996, <i>Eur. J. Cancer</i> , 32A(1):152-159.
	3	Aimes, et al., Cloning of a 72 kDa matrix metalloproteinase (gelatinase) from chicken embryo fibroblasts using gene family PCR: expression of the gelatinase increases upon malignant transformation, 1994, <i>Biochem J.</i> , 300:729-736.
	4	Friedlander, et al., Definition of two angiogenic pathways by distinct $\alpha\beta$ integrins, 1995, <i>Science</i> , 270:1500-1502.
	5	Pfaff, et al., Comparison of disintegrins with limited variation in the RGD loop in their binding to purified integrins $\alpha\text{IIb}\beta\text{3}$, $\alpha\beta\text{3}$ and $\alpha\beta\text{1}$ and in cell adhesion inhibition, 1994, <i>Cell Adhes. Commun.</i> , 2(6):491-501.
	6	Smith, et al., Interaction of integrins $\alpha\beta\text{3}$ and glycoprotein IIb-IIIa with fibrinogen, 1990, <i>J. Biol. Chem.</i> , 265:12267-12271.
	7	Mueller, et al., Pre-clinical therapy of human melanoma with morpholino-doxorubicin conjugated to a monoclonal antibody directed against an integrin on melanoma cells, <i>Antibody, Immunoconjugates, and Radiopharmaceuticals</i> , 1991, 4(2):99-106.
	8	Ossowski, et al., Experimental model for quantitative study of metastasis, 1980, <i>Cancer Res.</i> , 40:2300-2309.
<i>m</i>	9	Drake, et al., A antagonist of integrin $\alpha\beta\text{3}$ prevent maturation of blood vessels during embryonic neovascularization, 1995, <i>J. Cell Sci.</i> , 108:2655-2661.

EXAMINER

DATE CONSIDERED

Philip Gammie 5/28/01

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE			ATTY DOCKET NO. TSRI 419.0 Con 1	SERIAL NO. 09/081,522
			APPLICANT Brooks, et al.	
			FILING DATE May 19, 1998	GROUP 1644

U.S. PATENT DOCUMENTS

EXAM. INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

EXAM. INITIALS	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES NO
M	95/14714	6/1/95	PCT			


OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

M	10	Hammes, et al., Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization, 1996, <i>Nature Med.</i> , 2(5):529-533.
	11	Brooks, et al., Integrin $\alpha v\beta 3$ antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels, 1994, <i>Cell</i> , 79:1157-1164.
	12	Clark, et al, Transient functional expression of $\alpha v\beta 3$ on vascular cells during wound repair, 1996, <i>Am. J Pathol.</i> , 148:1407-1421.
	13	Bauer, et al., In vitro model of angiogenesis using a human endothelium-derived permanent cell line: contributions of induced gene expression, G-proteins and integrins, 1992, <i>J. Cell. Physiol.</i> , 153:437-449.
	14	Ingber, Extracellular matrix as a solid state regulator of angiogenesis: identification of new targets for anti-cancer therapy, 1992, <i>Seminars in Cancer Biology</i> , 3:57-63.
	15	Hardan, et al., Inhibition of metastatic cell colonization in murine lungs and tumor-induced morbidity by non-peptidic Arg-Gly-Asp mimetics, 1993, <i>Intl. J. Cancer</i> , 55:1023-1028.
	16	Hynes, Integrins: versatility, modulation, and signaling in cell adhesion, 1992, <i>Cell</i> , 69:11-25.
M	17	Lehmann, et al., A monoclonal antibody inhibits adhesion to fibronectin and vitronectin of a colon carcinoma cell line and recognizes the integrins $\alpha v\beta 3$, $\alpha v\beta 5$ and $\alpha v\beta 6$, 1994, <i>Cancer Res.</i> , 54:2102-2107.

EXAMINER	DATE CONSIDERED
Patricia Granger	5/28/01

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO. TSRI 419.0 Con 1	SERIAL NO. 09/081,522
		APPLICANT Brooks, et al.	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		FILING DATE May 19, 1998	GROUP 1644



U.S. PATENT DOCUMENTS

EXAM. INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE

RECEIVED
OCT 19 2001
TECH CENTER 1600/300

FOREIGN PATENT DOCUMENTS

EXAM. INITIALS	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

N	18	Pierschbacher, et al., Influence of stereochemistry of the sequence Arg-Gly-Asp-Xaa on binding specificity in cell adhesion, 1987, <i>J. Biol. Chem.</i> , 262:17294-17296.
/	19	Folkman, et al., Angiogenesis, 1992, <i>J. Biol. Chem.</i> , 267:10931-10934.
/	20	Teicher, et al., Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents, 1994, <i>Intl. J. Cancer</i> , 57:920-925.
M	21	Saiki, et al., Inhibition of tumor angiogenesis by a synthetic cell-adhesive polypeptide containing the Arg-Gly-Asp (RGD) sequence of fibronectin, poly (RGD), 1990, <i>Jpn. J. Cancer Res.</i> , 81:668-675.
	22	
	23	
	24	
	25	
	26	

EXAMINER	DATE CONSIDERED
Philip Gruber	5/28/01

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.